Novel adjuvant delivery system constructed by alum-emulsion hybrid nanoparticles with TLR9 agonists boosts vaccine immunity

由明矾乳液杂化纳米颗粒与TLR9激动剂构建的新型佐剂递送系统可增强疫苗免疫力

阅读:4
作者:Yarong Zeng # ,Yifan Yin # ,Jialin Xu # ,Rong Su ,Sibo Zhang ,Feng Han ,Yufang Li ,Xueqing Zhu ,Ciying Qian ,Feihong Zou ,Renfei Gao ,Xiuli Zhang ,Lizhi Zhou ,Tingting Li ,Min Lin ,Qingbing Zheng ,Hai Yu ,Jun Zhang ,Zizheng Zheng ,Ying Gu ,Ningshao Xia ,Shaowei Li

Abstract

Vaccine Adjuvant Delivery Systems (VADSs) that integrate both delivery and adjuvancy constitute a vital strategy in modern vaccine research. Herein, we employed microfluidics to blend nanosized aluminum hydroxide (XA) and a nanoemulsion (XE) in varying proportions. A 2:3 (v/v) mixture produced nanoparticles (XAE) of approximately 220 nm with near-neutral zeta potential, which significantly enhanced antigen uptake in DC2.4 cells and displayed stronger adjuvant activity than XA or XE alone. By electrostatically adsorbing the TLR9 agonist CpG onto XAE, we constructed XAEC as an integrated delivery platform that co-delivers antigens and immune-stimulatory molecules, thereby improving CpG's bioavailability and biocompatibility. This XAEC platform generated an "immune-activated microenvironment" at the injection site, fostering antigen-presenting cell (APC) recruitment, augmenting antigen presentation, facilitating vaccine trafficking to immune organs, and eliciting a Th1-biased immune response. XAEC substantially boosted immunogenicity in prophylactic Respiratory Syncytial Virus (RSV) and Varicella-Zoster Virus (VZV) vaccines and induced potent antitumor responses in a Human Papillomavirus (HPV) tumor model. Hence, XAEC emerges as a promising next-generation vaccine adjuvant system.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。